Cytochrome P450 2D6 Polymorphism and Its Impact on Decision-Making in Psychopharmacotherapy: Finding the Right Way in an Ultrarapid Metabolizing Patient

Michael Paulzen, MD; Simone C. Tauber, MD; André Kirner-Veselinovic, MD; and Gerhard Gründer, MD

Published: November 15, 2011

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

The cytochrome P450 (CYP) superfamily represents the most important phase I drug metabolizing enzyme system. Genetic mutations play an important role in the activity especially of CYP2D6. Genetic polymorphisms within CYPs affect the metabolism of drugs as substrates for the particular enzymes, resulting in variations in plasma levels of the drugs, differences in drug response, or altered risk for adverse effects.

Volume: 72

Quick Links: Assessment Methods , Genetics

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF

Sign-up to stay
up-to-date today!


Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...